Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, RemeGen Co's Enterprise Value is €6,917.7 Mil.
RemeGen Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil. Therefore, RemeGen Co's EV-to-OCF for today is .
The historical rank and industry rank for RemeGen Co's EV-to-OCF or its related term are showing as below:
STU:REG'
s EV-to-OCF Range Over the Past 10 Years
Min: -68.87 Med: -25.19 Max: 1136.53
Current: 1136.53
During the past 8 years, the highest EV-to-OCF of RemeGen Co was 1136.53. The lowest was -68.87. And the median was -25.19.
STU:REG's EV-to-OCF is ranked worse than 99.72% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs STU:REG: 1136.53
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RemeGen Co's share price for today is €8.694.
RemeGen Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.257.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
RemeGen Co EV-to-OCF Related Terms
RemeGen Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for RemeGen Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, RemeGen Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where RemeGen Co's EV-to-OCF falls into.
RemeGen Co's current Enterprise Value is €6,917.7 Mil.
RemeGen Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is RemeGen Co (STU:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €8.69 is trading 61.1% below its estimated GF Value™ of €22.36.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for STU:REG:
EV-to-OCF:
GF Value™: €22.36 vs. price of €8.69 (61.1% below fair value)
No single metric tells the full story. See the STU:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
50GF Score
Get the complete analysis for STU:REG
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:REG has been successfully added to your 
